Rezolute, Inc. — Form 10-Q Summary
Period clarification: The request metadata says “2019 Q3,” but this filing covers the quarter and nine months ended March 31, 2020 (Rezolute’s fiscal third quarter of 2020). The report was signed May 14, 2020.
Business context
Rezolute is a clinical-stage biopharmaceutical company with no commercial products or revenue. Its lead candidate, RZ358, is in Phase 2b development for congenital hyperinsulinism (CHI); RZ402 is a preclinical oral candidate for diabetic macular edema (DME). The company also reported that further development of AB101 requires formulation adjustments and that it is seeking a partner to out-license the program.
Financial performance and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | None in 2020 or 2019 | None in 2020 or 2019 |
| R&D expense | $3.7m vs. $15.1m | $12.0m vs. $17.4m |
| G&A expense | $1.3m vs. $1.9m | $5.0m vs. $5.4m |
| Operating loss | $5.1m vs. $17.0m | $17.0m vs. $22.8m |
| Net loss | $5.0m vs. $19.8m | $16.8m vs. $27.3m |
| Operating cash used | Not provided for the quarter | $20.1m vs. $11.5m |
Lower comparative-period losses largely reflect $14.0m of Xoma licensing expense and $4.9m of interest expense recorded in the prior-year nine-month period, rather than lower current-period operating needs. Current-period R&D spending excluding that prior-year licensing charge rose, reflecting clinical work, staff, and development services. No meaningful operating margin is applicable because the company had no revenue.
At March 31, 2020, cash and cash equivalents were $14.0m, working capital was $10.6m, total assets were $14.7m, total liabilities were $4.4m, and stockholders’ equity was $10.3m. Cash was $11.6m at June 30, 2019. The company reported no interest expense in the current periods and no cash paid for interest; disclosed liabilities include Xoma license payments and operating leases, not just financial borrowings. Accumulated deficit was $143.7m.
Financing activities provided $22.6m net cash in the nine months, following July–August 2019 private placements that raised $24.1m gross. Common shares outstanding increased from 210.4m at June 30, 2019 to 293.3m at March 31, 2020; the July–August issuance accounted for approximately 82.9m shares.
Material changes, outlook, and risks
- Clinical outlook: COVID-19 paused new site initiation and enrollment in the RZ358 Phase 2b RIZE study. Management said that if the study could resume by October 2020, it expected completion before the end of Q3 2021. RZ402’s IND filing remained planned for Q3 2020, but the timing of a Phase 1 study was uncertain.
- Liquidity and going concern: Management expected existing cash to fund planned activities through the end of calendar 2020 and said financing would be needed by year-end 2020 to advance programs in 2021. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Management may delay clinical programs to conserve cash; future financing availability and terms are uncertain.
- COVID-19: The pandemic could delay trials, increase costs for patient and staff safeguards, disrupt operations and make financing harder. Its duration and financial impact could not be reasonably estimated.
- Xoma obligation: Amendment No. 3, signed March 31, 2020, extended payment timing for the remaining license obligation. The balance was approximately $2.2m at March 31, including $1.6m current and $0.6m long-term, with payments scheduled through September 2021. Future RZ358 royalties and milestone payments also apply under the license.
- Other obligations: The ActiveSite agreement provides for up to $46.5m in milestone payments and 2% royalties; no milestone payment or royalty had been triggered by March 31, 2020. Xoma may also exercise a put option covering specified shares the company holds.
- Controls and unusual items: Management determined internal control over financial reporting was not effective, citing weaknesses in segregation of duties, override prevention, complex accounting review, and review of financial reporting and disclosures. A full valuation allowance meant no income tax benefit was recorded. The board had authority to effect a 1-for-20 to 1-for-100 reverse split but had not done so by the report date.
Most important facts for investors to verify
- Whether additional financing was completed by the stated year-end 2020 need, and on what terms and dilution.
- Whether RIZE enrollment resumed and whether the trial timeline and costs changed.
- Whether RZ402 filed its IND as planned and when clinical testing began.
- Actual cash burn, runway, and Xoma payment status relative to the disclosed schedule.
- Whether internal-control weaknesses were remediated and whether any reverse split or national-exchange uplisting occurred.